Vyne Therapeutics Stock Total Asset
| VYNE Stock | USD 3.03 0.13 4.48% |
Vyne Therapeutics fundamentals help investors to digest information that contributes to Vyne Therapeutics' financial success or failures. It also enables traders to predict the movement of Vyne Stock. The fundamental analysis module provides a way to measure Vyne Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vyne Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 97.7 M | 82 M |
Vyne | Total Asset |
Vyne Therapeutics Company Total Asset Analysis
Vyne Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Vyne Therapeutics Total Asset | 97.69 M |
Most of Vyne Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vyne Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vyne Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Vyne Therapeutics is extremely important. It helps to project a fair market value of Vyne Stock properly, considering its historical fundamentals such as Total Asset. Since Vyne Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vyne Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vyne Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Vyne Total Asset Historical Pattern
Today, most investors in Vyne Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vyne Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vyne Therapeutics total asset as a starting point in their analysis.
Vyne Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Vyne Total Assets
Total Assets |
|
Based on the latest financial disclosure, Vyne Therapeutics has a Total Asset of 97.69 M. This is 98.7% lower than that of the Biotechnology sector and 95.06% lower than that of the Health Care industry. The total asset for all United States stocks is 99.67% higher than that of the company.
Vyne Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vyne Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vyne Therapeutics could also be used in its relative valuation, which is a method of valuing Vyne Therapeutics by comparing valuation metrics of similar companies.Vyne Therapeutics is currently under evaluation in total asset category among its peers.
Vyne Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vyne Therapeutics from analyzing Vyne Therapeutics' financial statements. These drivers represent accounts that assess Vyne Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vyne Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 157.5M | 204.9M | 52.5M | 8.6M | 9.9M | 9.4M | |
| Enterprise Value | 127.4M | 182.1M | 10.6M | (22.7M) | (26.1M) | (24.8M) |
Vyne Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vyne Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vyne Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vyne Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Vyne Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vyne Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vyne Therapeutics' value.| Shares | Adar1 Capital Management Llc | 2024-06-30 | 171.2 K | Geode Capital Management, Llc | 2024-06-30 | 135.7 K | Renaissance Technologies Corp | 2024-09-30 | 86.6 K | Springbok Capital Management, Llc | 2024-06-30 | 65 K | Blackrock Inc | 2024-06-30 | 60.6 K | Susquehanna International Group, Llp | 2024-06-30 | 60.3 K | Northern Trust Corp | 2024-09-30 | 37.3 K | Ubs Group Ag | 2024-06-30 | 25.1 K | State Street Corp | 2024-06-30 | 15.8 K | Eventide Asset Management, Llc | 2024-06-30 | 1.4 M | Cormorant Asset Management, Llc | 2024-06-30 | 1.4 M |
Vyne Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (52.51) % | ||||
| Current Valuation | (27.28 M) | ||||
| Shares Outstanding | 14.75 M | ||||
| Shares Owned By Insiders | 8.31 % | ||||
| Shares Owned By Institutions | 56.03 % | ||||
| Number Of Shares Shorted | 82.56 K | ||||
| Price To Book | 0.67 X | ||||
| Price To Sales | 86.77 X | ||||
| Revenue | 424 K | ||||
| Gross Profit | 477 K | ||||
| EBITDA | (29.26 M) | ||||
| Net Income | (28.45 M) | ||||
| Cash And Equivalents | 42.81 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 214 K | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 6.29 X | ||||
| Cash Flow From Operations | (25.34 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | 1.72 X | ||||
| Target Price | 5.58 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 44.25 M | ||||
| Total Asset | 97.69 M | ||||
| Retained Earnings | (691.34 M) | ||||
| Working Capital | 88.42 M | ||||
| Net Asset | 97.69 M |
About Vyne Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vyne Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out Vyne Therapeutics Piotroski F Score and Vyne Therapeutics Altman Z Score analysis. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.